Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 C12, C13: Hypopharynx cancer

Year of diagnosis	1988-1997	1998-2014
Patients	450	1,508
Diseases	451	1,508
Cases evaluated	403	1,181
Creation date	03/02/2016	
Export date	12/23/2015	
Population	4.64 m	





Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

http://www.tumorregister-muenchen.de/en/facts/surv/sC1213E-ICD-10-C12-C13-Hypopharynx-cancer-survival.pdf




Figure 1a. Relative survival of patients with hypopharynx cancer by period of diagnosis. Included in the evaluation are 1,580 cases diagnosed between 1988 and 2014.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	F	Period	of diag	gnosis	5	
	1988-	1997	1998-	2006	200)7+
	n=4	102	n=6	605	n=5	573
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0		100.0	100.0	100.0
1	69.7	70.6	66.7	67.6	65.1	66.0
2	47.0	48.2		47.0	48.3	49.8
3	35.3	36.5		37.0	40.9	42.8
4	29.1	30.5	30.9	32.5	34.1	36.1
5	25.9	27.5	27.5	29.4	30.7	33.2
6	23.1	25.1	24.4	26.3	24.9	27.3
7	22.9	24.9		25.1	23.4	26.1
8	21.8	24.3	21.2	23.6		
9	19.9	22.5		22.2		
10	18.8	21.5	18.2	21.0		
11	16.6	19.4	17.1	19.7		
12	14.6	17.2	14.9	17.8		
13	13.5	16.3	14.9	17.6		
14	12.3	15.1	12.9	16.1		
15	11.5	14.5				
16	11.2	14.2				
17	10.7	13.9				
18	10.1	13.2				
19	9.3	12.9				
20	8.9	12.5				

Table 1b. Observed (obs.) and relative (rel.) survival of patients with hypopharynx cancer by period of diagnosis for period 1988-2014 (N=1,580).






Figure 2a. Survival of patients with hypopharynx cancer by gender. Included in the evaluation are 1,580 cases diagnosed between 1988 and 2014.

	C	Sende	r		
	Ma	ale	Ferr	nale	
	n=1,	399	n=1	81	
Years	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	
1	67.0	68.0	66.0	66.4	
2	46.4	47.8	51.0	51.7	
3	36.7	38.3	41.9	43.0	
4	30.7	32.5	38.2	39.4	
5	27.3	29.5	34.2	35.1	
6	23.9	26.1	29.9	31.5	
7	22.7	25.2	29.9	31.3	
8	21.0	23.7	29.9	31.2	
9	19.4	22.3	26.7	28.6	
10	18.1	21.2	25.3	27.4	
11	16.3	19.4	23.9	25.3	
12	14.7	17.8			
13	14.1	17.4			
14	13.0	16.5			
15	12.2	15.8			
16	12.0	15.6			
17	11.3	15.2			
18	10.9	14.7			
19	10.0	14.2			
20	9.5	13.7			

Table 2b. Observed (obs.) and relative (rel.) survival of patients with hypopharynx cancer by gender for period 1988-2014 (N=1,580).




Figure 3a. Relative survival of patients with hypopharynx cancer by age category. Included in the evaluation are 1,580 cases diagnosed between 1988 and 2014.

			Age	categ	ory			
	0-49	yrs	50-59	9 yrs –	60-69	9 yrs	70+	yrs
	n=2	63	n=6	611	n=4	90	n=2	216
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	73.2	73.1	70.6	71.1	63.4	64.4	56.5	59.1
2	54.1	54.3	47.5	48.2	46.5	47.9	37.6	41.4
3	43.9	44.2	38.1	38.8	37.3	39.0	26.8	30.4
4	40.0	40.2	31.9	32.8	31.0	33.1	20.7	24.7
5	35.9	36.5	28.2	29.2	28.9	31.7	15.6	19.5
6	31.9	32.7	25.4	26.6	25.0	27.7		
7	30.9	31.5	24.5	25.8	23.7	27.1		
8	30.4	31.0	22.3	23.8	22.6	26.3		
9	29.7	30.6	20.2	21.8	20.1	24.0		
10	29.1	30.0	18.9	20.7	18.0	21.9		
11	27.6	29.0	16.7	18.4	16.1	20.2		
12	24.3	25.7	14.3	15.9	14.7	19.6		
13	23.4	24.7	13.5	15.2	13.9	18.7		
14	22.5	23.5	11.6	13.7				
15	21.6	22.9	10.2	12.2				
16	20.6	21.8	10.2	12.2				
17	19.5	20.8	10.2	12.1				
18	18.3	19.3	10.2	12.1				

Table 3b. Observed (obs.) and relative (rel.) survival of patients with hypopharynx cancer by age category for period 1988-2014 (N=1,580).




Figure 4a. Relative survival of patients with hypopharynx cancer by TNM staging. For 1,490 of 1,580 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 1,478 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 102 patients with missing values regarding TNM staging (6.5% of 1,580 patients, the percent values of all other categories are related to n=1,478).

	TNM staging													
	Т	1	Т	2	T3	T3+4		T3+4 N0 N+		+	N	Х	NA/NOS	
	n=1	141	n=2	263	n=1,	n=1,051		258	n=1,163		n=38		n=102	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	87.7	88.3	84.3	85.1	63.0	64.0	84.3	85.6	66.3	67.1	59.5	59.0	34.8	35.4
2	72.1	73.7	65.1	66.6	41.8	43.0	68.5	70.7	44.7	45.9			24.6	25.6
3	59.0	60.7	53.5	55.1	32.7	34.1	56.8	59.7	35.3	36.6			18.4	19.0
4	54.9	57.1	46.4	48.5	26.8	28.4	50.2	53.5	29.6	31.1				
5	50.6	53.8	42.8	45.6	23.5	25.2	47.0	50.7	25.9	27.7				
6	45.8	49.6	36.4	39.2	20.5	22.2	43.5	47.9	22.2	23.9				
7	44.8	49.0	34.8	37.6	19.4	21.4	41.8	46.3	21.3	23.3				
8	42.5	46.5	32.9	36.7	17.9	20.0	40.1	45.0	19.5	21.7				
9	38.8	43.0	32.9	36.7	16.0	18.2	36.9	42.2	18.1	20.5				
10	36.2	41.6	32.1	36.0	14.8	17.1	33.9	39.4	17.2	19.7				

Table 4b. Observed (obs.) and relative (rel.) survival of patients with hypopharynx cancer by TNM staging for period 1988-2014 (N=2,914).




Figure 4c. Relative survival of patients with hypopharynx cancer by TNM staging. For 1,104 of 1,178 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 1,094 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 84 patients with missing values regarding TNM staging (7.1% of 1,178 patients, the percent values of all other categories are related to n=1,094).

	TNM staging															
	Т	1	Т	2	Т3	T3+4		N0 N+		+	NX		NA/NOS			
	n=1	110	n=2	202	n=7	n=765		n=765		n=174		373	n=	33	n=84	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %		
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0		
1	87.9	88.3	84.5	85.3	62.4	63.4	85.4	86.7	65.9	66.8	59.4	57.8	29.4	29.8		
2	69.6	71.0	64.9	66.5	42.2	43.3	70.6	72.8	45.3	46.4			23.3	23.3		
3	56.4	57.7	53.3	54.9	34.2	35.6	62.4	65.5	35.8	37.2						
4	51.9	54.1	47.9	50.2	28.4	30.1	54.4	58.0	30.6	32.2						
5	48.3	51.3	44.8	48.0	24.7	26.5	51.5	55.7	26.8	28.7						
6	44.2	47.9	38.6	41.8	20.8	22.6	48.3	53.4	22.4	24.1						
7	42.5	46.8	37.1	40.2	19.3	21.1	46.5	51.4	21.0	23.1						
8	40.5	43.6	34.2	38.5	17.6	19.6	44.6	49.9	19.0	21.0						
9	36.5	39.3	34.2	38.5	15.8	17.9	41.1	47.0	17.6	20.0						
10			34.2	38.5	14.6	16.8	35.0	40.4	17.2	19.8						

Table 4d. Observed (obs.) and relative (rel.) survival of patients with hypopharynx cancer by TNM staging for period 1998-2014 (N=2,157).

ICD-10 C12, C13: Malignant neoplasm of hypopharynx incl. piriform sinus




Figure 5a. Time to first progression of 1,074 patients with hypopharynx cancer diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression											
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)					
	n=1,074	n=1,074	n=1,074	n=1,074	n=1,074	n=1,074	n=1,074					
Years	%	%	%	%	%	%	%					
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0					
1	36.4	38.0	5.9	7.7	3.0	3.8	13.7					
2	51.9	55.5	11.5	17.0	4.5	6.3	23.4					
3	55.9	60.4	12.6	19.4	5.1	7.7	27.1					
4	57.9	63.0	12.8	20.0	5.3	8.3	28.0					
5	59.0	64.5	13.2	21.0	5.6	9.4	29.1					
6	60.4	66.6	13.8	23.1	5.6	9.4	29.5					
7	61.0	67.6	14.2	24.2	5.8	10.0	29.7					
8	61.2	67.9	14.2	24.2	5.8	10.0	29.7					
9	61.5	68.6	14.4	25.0	5.8	10.0	29.9					
10	61.5	68.6	14.4	25.0	5.8	10.0	29.9					

	Type of progression									
	Distant									
cont'd	metast. (1- KM)	NOS (CI)	NOS (1-KM)							
	n=1,074	n=1,074	n=1,074							
Years	%	%	%							
0	0.0	0.0	0.0							
1	16.1	4.2	5.5							
2	30.1	6.4	9.5							
3	36.5	6.5	9.8							
4	38.2	6.7	10.1							
5	40.6	6.8	10.5							
6	41.6	6.9	11.1							
7	42.0	6.9	11.1							
8	42.0	6.9	11.1							
9	42.6	6.9	11.1							
10	42.6	6.9	11.1							

Table 5b. Time to first progression of patients with hypopharynx cancer for period 1998-2014 (N=1,074).






Figure 5c. Observed post-progression survival of 448 patients with hypopharynx cancer diagnosed between 1998 and 2014. These 448 patients with documented progression events during their course of disease represent 38.1 % of the totally 1,176 evaluated cases (incl. M1, n=102, 8.7 %). Patients with cancer relapse documented via death certificates only were excluded (n=292, 24.8 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

			Type of	f progressio	n	
		Any type	Local relapse	Lymph node	Distant metastasis	NOS
		n=448	n=153	n=61	n=280	n=74
	Years	%	%	%	%	%
	0	100.0	100.0	100.0	100.0	100.0
	1	32.6	33.4	32.7	29.2	31.1
	2	18.7	15.5		15.6	
	3	13.3			11.4	
	4	10.9			8.8	
	5	9.1				
	6	7.9				
	7	7.4				
	8	7.4				
	9	7.4				
	10	7.4				

Table 5d. Observed post-progression survival of patients with hypopharynx cancer for period 1998-2014 (N=448).




Figure 5e. Observed post-progression (distant metastasis) survival of 354 patients with hypopharynx cancer diagnosed between 1988 and 2014 by period of progression.

	Period o	of progressio	n
	1988-1997	1998-2006	2007+
	n=58	n=145	n=151
Years	%	%	%
0	100.0	100.0	100.0
1	26.4	20.1	36.4
2			21.1
3			16.0
4			12.7

Table 5f. Observed post-progression (distant metastasis) survival of patients with hypopharynx cancer for period 1988-2014 by period of progression (N=354).

Shortcuts

MCR	Munich Cancer Registry, Germany								
NCI	National Cancer Institute, L	JSA							
SEER	Surveillance, Epidemiology	, and End Results, USA							
UICC	Union for International Can	cer Control, Geneva							
DCO	Death certificate only	Death certificate provides the only notification to the registry.							
NA	Not available								
NOS	Not otherwise specified								
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause							
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival							
AS	Assembled survival	Assembled chart of observed, expected, relative survival							
CS	Conditional survival	Survival probability under the condition of surviving a given period of time							
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression							
	1-КМ	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)							
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)							
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause							

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C12, C13: Hypopharynx cancer [Internet]. 2016 [updated 2016 Mar 2; cited 2016 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/sC1213E-ICD-10-C12-C13-Hypopharynx-cancer-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl		Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	3
2a	Survival by gender (chart)	4
2b	Survival by gender (table)	4
3a	Relative survival by age category (chart)	5
3b	Survival by age category (table)	5
4a	Relative survival by TNM staging 1988+ (chart)	6
4b	Survival by TNM staging 1988+ (table)	6
4c	Relative survival by TNM staging 1998+ (chart)	7
4d	Survival by TNM staging 1998+ (table)	7
5a	Time to first progression (chart)	8
5b	Time to first progression (table)	8
5c	Observed post-progression survival (chart)	10
5d	Observed post-progression survival (table)	10
5e	Observed post-progression survival by period of progression (chart)	11
5f	Observed post-progression survival by period of progression (table)	11